Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VU2X
|
|||
| Former ID |
DAP000098
|
|||
| Drug Name |
Conivaptan
|
|||
| Synonyms |
Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Euvolemic hyponatremia [ICD-11: 5C72; ICD-10: E87.1; ICD-9: 276.1] | Approved | [1], [2] | |
| Company |
Astellas Pharma Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H26N4O2
|
|||
| Canonical SMILES |
CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
|
|||
| InChI |
1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
|
|||
| InChIKey |
IKENVDNFQMCRTR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 210101-16-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14933230, 46227736, 46504533, 46539970, 47285936, 47583799, 50070653, 50300910, 57347309, 85209766, 85210128, 93608331, 96024467, 99299517, 103707723, 104154132, 104430350, 125824483, 128179844, 134337425, 134338921, 134340688, 134340689, 135106955, 135651340, 136351195, 137005849, 137263556, 138069836, 140034093, 142385717, 152057312, 160964213, 172085102, 174006907, 175266283, 179225632, 179293751, 184528844, 196109797, 223957134, 226433457, 244302846, 251971383, 252215185
|
|||
| ChEBI ID |
CHEBI:681850
|
|||
| ADReCS Drug ID | BADD_D00526 ; BADD_D00527 | |||
| SuperDrug ATC ID |
C03XA02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1a receptor (V1AR) | Target Info | Modulator | [3], [4] |
| Vasopressin V2 receptor (V2R) | Target Info | Modulator | [3], [4] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Vasopressin-regulated water reabsorption | ||||
| Calcium signaling pathway | ||||
| Vascular smooth muscle contraction | ||||
| Pathwhiz Pathway | Vasopressin Regulation of Water Homeostasis | |||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (s) signalling events | ||||
| Vasopressin regulates renal water homeostasis via Aquaporins | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Regulation of Water Balance by Renal Aquaporins | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2203). | |||
| REF 2 | Emerging diuretics for the treatment of heart failure. Expert Opin Emerg Drugs. 2009 Mar;14(1):195-204. | |||
| REF 3 | Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. | |||
| REF 4 | Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.